44
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention

      review-article

      Read this article at

      ScienceOpenPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Low-density lipoprotein (LDL) cholesterol concentration has been the prime index of cardiovascular disease risk and the main target for therapy. However, several lipoprotein ratios or “atherogenic indices” have been defined in an attempt to optimize the predictive capacity of the lipid profile. In this review, we summarize their pathophysiological aspects, and highlight the rationale for using these lipoprotein ratios as cardiovascular risk factors in clinical practice, specifying their cut-off risk levels and a target for lipid-lowering therapy. Total/high-density lipoprotein (HDL) cholesterol and LDL/HDL cholesterol ratios are risk indicators with greater predictive value than isolated parameters used independently, particularly LDL. Future recommendations regarding the diagnosis and treatment of dyslipidemia, including instruments for calculating cardiovascular risk or action guidelines, should include the lipoprotein ratios with greater predictive power which, in view of the evidence-based results, are none other than those which include HDL cholesterol.

          Related collections

          Author and article information

          Journal
          Vasc Health Risk Manag
          Vascular Health and Risk Management
          Vascular Health and Risk Management
          Dove Medical Press
          1176-6344
          1178-2048
          2009
          2009
          18 September 2009
          : 5
          : 757-765
          Affiliations
          [1 ] Hospital Universitario Gregorio Marañón, Madrid, Spain
          [2 ] Hospital Universitario Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain
          [3 ] Solvay Pharma, Barcelona, Spain
          [4 ] Hospital Marqués de Valdecilla, Santander, Spain
          [5 ] Hospital Vall d’Hebrón, Barcelona, Spain
          [6 ] Hospital Universitario La Paz, Madrid, Spain
          [7 ] Hospital Sant Joan, Reus, Tarragona, Spain
          [8 ] Hospital Universitario Puerta del Mar, Cádiz, Spain
          [9 ] Hospital Universitario Dr Peset, Valencia, Spain
          [10 ] Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain
          [11 ] Hospital Clínico Universitario, Valencia, Spain
          [12 ] Hospital del Mar, Barcelona, Spain
          Author notes
          Correspondence: Anna Muñoz, Solvay Pharma, Av. Diagonal, 507, 08029, Barcelona, Spain, Tel +34 93 495 4500, Fax +34 93 430 3727, Email anna.munoz@ 123456solvay.com
          Article
          vhrm-5-757
          2747394
          19774217
          0624f390-61c6-455d-a69a-e0854225ceb6
          © 2009 Millán et al, publisher and licensee Dove Medical Press Ltd.

          This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.

          History
          Categories
          Mini-Review

          Cardiovascular Medicine
          cholesterol ratios,cardiovascular disorders,apolipoproteins,predictive power

          Comments

          Comment on this article